About this trial
Hypothyroidism is a thyroid disorder and one of the most common endocrine disorders. Hypothyroidism can have multiple causes; most patients suffer from primary autoimmune hypothyroidism (Hashimoto's disease), but also central hypothyroidism, hypothyroidism after total thyroidectomy due to thyroid carcinoma, or hypothyroidism due to therapy of Graves' disease occur. Most patients with hypothyroidism are treated with levothyroxine (L-T4) to supplement the lack of thyroxine (T4) produced by their own thyroid. Serum thyroid-stimulating hormone (TSH) and/or free T4 (fT4) are currently measured to assess the efficacy of this therapy and to establish euthyroidism. It is known that fT4 concentrations in patients using L-T4 can be above the upper limit of the reference interval, while their TSH is not (completely) suppressed. This raises the question whether fT4 is an accurate reflection of thyroid hormone status in patients using L-T4. TSH is considered a reliable parameter of thyroid hormone status; however, TSH cannot be used to assess thyroid function in specific hypothyroid patient groups (e.g. central hypothyroidism). Free triiodothyronine (fT3), the active thyroid hormone, has been suggested to be an interesting alternative of fT4 to assess thyroid function. Previously, the methods to measure fT3 were not that robust; however, methods to determine fT3 have been improved, are currently reliable and not susceptible to changes due to L-T4 intake. In addition, the fT3/fT4 ratio is thought to be an interesting candidate in assessing thyroid hormone status as well. The aim of this study is to improve laboratory diagnostics of thyroid hormone status in patients with hypothyroidism receiving L-T4 in whom TSH cannot be used as a reflection of thyroid hormone status. We will primarily investigate the additional already available laboratory tests fT3 and fT3/fT4 ratio. We hypothesize that treated hypothyroid participants who are assumed euthyroid based on TSH (e.g. patients with Hashimoto's hypothyroidism) but have fT4 concentrations above the upper reference limit will more often have a fT3 level or a fT3/fT4 ratio within the reference interval. Concentrations of alternative markers in healthy controls and patients with Hashimoto's hypothyroidism with 'normal' TSH concentrations can, thus, be used to predict thyroid hormone status in patients using L-T4 in whom TSH cannot be used to assess thyroid hormone status.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Ability to provide informed consent
Ability to speak and understand Dutch or English
Intake of a stable dosage of levothyroxine, meaning the dosage of levothyroxine must not be changed during the appointment at the outpatient clinic
Diagnosis of one these forms of hypothyroidism
Disqualifiers
Not euthyroid according to physician
Pregnancy
Patients using L-T4 due to therapy of Graves' disease: if TSH is still suppressed
Any of the following medication
Trial population
Adults with hypothyroidism using levothyroxine (L-T4) attending the outpatient clinic of Amsterdam UMC will be included. Healthy euthyroid controls will be recruited amongst employees of Amsterdam UMC.
Trial design
Other
Cross-sectional
Treatments tested in this trial
Single extra blood draw and completion of single questionnaire
Other interventionSingle blood draw of 3 tubes (20 mL) additional to regular blood draw will be performed. All participants will complete a single questionnaire that will be 5-10 minutes time-consuming.
Single blood draw and completion of single questionnaire
Other interventionSingle blood draw of 3 tubes (20 mL) will be performed. All participants will complete a single questionnaire that will be 5-10 minutes time-consuming.
Treatment groups
Trial outcomes
Primary outcomes
TSH concentration
Laboratory measurement
fT4 concentration
Laboratory measurement
fT3 concentration
Laboratory measurement
fT3/fT4 ratio
Ratio derived from abovementioned laboratory measurements
Secondary outcomes
TT4 concentration
Laboratory measurement
TT3 concentration
Laboratory measurement
rT3 concentration
Laboratory measurement
SHBG
Laboratory measurement
Other outcomes
ThyPRO-39
Questionnaire
DIO polymophisms
Laboratory measurement
Sex
Questionnaire; patient characteristics
Age
Questionnaire; patient characteristics
Sponsors and contacts
Click on the lead sponsor to view all of their trials.